About
Regenera Pharma is a clinical-stage pharmaceutical company developing innovative drugs for the treatment of optic nerve neuropathies. The company is currently focused on a treatment for ischemic optic neuropathy. Regenera will conduct a phase 3 study in the U.S. for evaluating the efficacy and safety of RPh201 treatment in participants diagnosed with NAION. It will also commence a phase 2 study in Canada that will evaluate the safety, tolerability, and clinical benefit of RPh201 in individuals with Alzheimers disease, with or without coexisting cerebrovascular disease. Regenera collaborates with the Henry Ford Health System to investigate the therapeutic effects of RPh201 on stroke recovery in a rat model of embolic middle cerebral artery occlusion (MCAO).
Funding history · 4 rounds · $24.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the current operational status of Regenera Pharma?
- Regenera Pharma is currently inactive, having ceased operations in November 2020.
- When was Regenera Pharma founded and what was its primary focus?
- Regenera Pharma was founded in June 2008 as a clinical-stage pharmaceutical company focused on developing innovative drugs for optic nerve neuropathies, specifically ischemic optic neuropathy.
- What was the total amount of funding raised by Regenera Pharma?
- Regenera Pharma raised a total of $24,025,000 across its funding rounds. For a full financing history, please refer to startupim.
- Which investor participated in Regenera Pharma's Series B funding round?
- aMoon Fund was an investor in Regenera Pharma's Series B round in January 2018.
- What was the last funding round for Regenera Pharma?
- Regenera Pharma's last funding round was a Series B in January 2018, which raised $20,000,000.
- What clinical studies was Regenera Pharma conducting for its drug RPh201?
- Regenera Pharma was conducting a Phase 3 study in the U.S. for RPh201 in participants with NAION and a Phase 2 study in Canada for RPh201 in individuals with Alzheimer's disease.
- With which institution did Regenera Pharma collaborate to investigate RPh201's effects on stroke recovery?
- Regenera Pharma collaborated with the Henry Ford Health System to investigate RPh201's therapeutic effects on stroke recovery in a rat model.
- When did Regenera Pharma announce the publication of its RPh201 Phase 2a study data?
- In May 2019, Regenera Pharma announced the publication of its RPh201 Phase 2a study data for the treatment of NAION in the Journal of Neuro-Ophthalmology.
- What was the employee count for Regenera Pharma?
- Regenera Pharma had an employee count in the range of 1-10.